CClinicalTrials.gg
CompletedNCT02465476TelemalraresUpdated Nov 20, 2018

Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine

An interventional study of telemedicine in Skin Disease, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2018-11-20.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2015, registered Apr 2015).
Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Sex
All
01

Study summary

The investigators want to demonstrate that a new organization with telemedicine could rationalize the treatment pathway of patient suffering from rare skin disease. A diagnosis and a personalised treatment pathway could be performed before the consultation in the hospital.

02

Conditions studied

  • Skin Disease

Browse trials for

Keywords

  • skin disease
  • telemedicine
03

In context

Skin Diseases

537 studies on the registry are indexed under Skin Diseases; 91 are open to participants now.

This study's enrollment of 212 is above the median of 60 across 371 interventional studies indexed under Skin Diseases.

Browse Skin Diseases studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • New patients suffering from a rare skin disease whatever pathology or age, which needs a take-over by this centre
  • Or patients already take-over by the centre but lost to follow-up for more than one year
  • Patients (and/or parents) who give their consents
  • Patients (and/or parents) able to fill in questionnaires

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women.
  • Patients subject to a judicial safeguard order
  • Patients who need an emergency take-over
  • Patients followed by a doctor who does not have a computerized system or refuse to send data via the secured messaging
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (actual)

Study arms

  • No intervention
    normal care

    patient who will have normal treatment pathway

  • Experimental
    telemedicine

    patient who will have telemedicine

    Procedure: telemedicine

Interventions

  • Proceduretelemedicine

    treatment pathway organized by telemedicine

06

What researchers measure

Primary outcomes

  1. Number of hospital visits

    Interest of a procedure of telemedicine on the organization of the treatment pathway of patients affected by rare skin diseases in terms of change of the number of visit in hospital.

    Time frame: 6 months

Secondary outcomes

  1. Improvement of the treatment pathway and its organization

    Traceability in the information system by composite criteria : number of completed application forms, number of meeting per month, number of meeting a month, number of patients treated a month, time dedicated to the logistical coordination (collection by sheets of weekly time) and number of new patients per month.

    Time frame: 6 months

  2. Satisfaction of the patient

    questionnaire of satisfaction Short Form-36 Health Survey (SF36)

    Time frame: 6 months

  3. Change of the cost related to the patient care (direct and indirect).

    Composite criteria with number of consultations and hospitalizations, number of visit in hospital and number of days of work and school absenteeism.

    Time frame: 6 months

  4. management of time by the medical personal.

    collection by sheets of weekly time

    Time frame: 6 months

07

Study locations

1 site
  • UHToulouse
    Toulouse, 31059, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02465476
Lead sponsor
University Hospital, Toulouse
Responsible party
Sponsor
First posted
Jun 8, 2015
Start date
Jan 6, 2015
Primary completion
May 30, 2018
Completion
May 30, 2018
Last update
Nov 20, 2018

Study contacts

Juliette Mazereeuw-Hautier, MD . PHD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion